NWAAF_10
عضو نشط
- التسجيل
- 1 أكتوبر 2001
- المشاركات
- 167
السلام عليكم
اخي ابو على لو تعطيني مريئتكم عن سهم BIOM
والاخوه ما قصروا عطار وممدوح الله يعطيهم العافيه قول وفعل الله يجزاكم كل خيررررررررررررررر
لكن بعد الخبر هذا طاح ونزل ..
واخر اخباره هوBiomira Announces U.S. $16.3 Million Financing
Market Wire, Monday, September 22, 2003 at 09:06
Biomira Inc. (NASDAQ: BIOM) (TSX: BRA)
announced today that it has arranged a financing, totaling U.S.$16,290,000,
with Rodman & Renshaw, Inc. of New York acting as exclusive placement
agent. In respect of this financing, Biomira intends to file shortly in
Canada a prospectus supplement to its April 30, 2002 Base Shelf Prospectus
and in the United States a prospectus supplement to its April 30, 2002 F-10
Registration Statement. The financing is expected to close at the earliest
opportunity.
The Company will be offering up to 9 million common shares at an issue
price of U.S.$1.81, which represents a premium of 7.6 per cent over the
U.S.$1.682 average of the closing bid price of Biomira common shares as
quoted on the Nasdaq National Market for the five trading days up to and
including September 18, 2003.
The issue will include up to 2,070,000 warrants. Each purchaser
participating in the offering will receive 0.23 warrants for every common
share purchased in the offering. Each warrant will entitle the holder
thereof to purchase one common share at an exercise price of U.S. $2.30.
The warrants will have a two year term, expiring September 18, 2005, and a
"no exercise period" of six months.
"Our financial goal is to have sufficient funds to aggressively move our
two lead product candidates to the next level," said Edward Taylor, Vice
President Finance and Chief Financial Officer. "With the completion of
this additional financing, we feel we are well on the way to accomplishing
that goal."
Biomira is a biotechnology company specializing in the development of
innovative therapeutic approaches to cancer management. Biomira's
commitment to the treatment of cancer currently focuses on the development
of synthetic vaccines and novel strategies for cancer immunotherapy. We
are The Cancer Vaccine People™.
This release may contain forward-looking statements. Various factors could
cause actual results to differ materially from those projected in
forward-looking statements, including those predicting the timing and
results of clinical trials, availability or adequacy of financing, the
sales and marketing of commercial products or the efficacy of products.
Although the Company believes that the forward-looking statements contained
herein are reasonable, it can give no assurance that the Company's
expectations are correct. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement.
ودي استثمر فيه 500 الف ريال ومتردد لكن سعره 1.85 دولار
اتمنى القى رد منكم اخي سيف العجمي
وبالتوفيق للجميع وتحياتي
اخي ابو على لو تعطيني مريئتكم عن سهم BIOM
والاخوه ما قصروا عطار وممدوح الله يعطيهم العافيه قول وفعل الله يجزاكم كل خيررررررررررررررر
لكن بعد الخبر هذا طاح ونزل ..
واخر اخباره هوBiomira Announces U.S. $16.3 Million Financing
Market Wire, Monday, September 22, 2003 at 09:06
Biomira Inc. (NASDAQ: BIOM) (TSX: BRA)
announced today that it has arranged a financing, totaling U.S.$16,290,000,
with Rodman & Renshaw, Inc. of New York acting as exclusive placement
agent. In respect of this financing, Biomira intends to file shortly in
Canada a prospectus supplement to its April 30, 2002 Base Shelf Prospectus
and in the United States a prospectus supplement to its April 30, 2002 F-10
Registration Statement. The financing is expected to close at the earliest
opportunity.
The Company will be offering up to 9 million common shares at an issue
price of U.S.$1.81, which represents a premium of 7.6 per cent over the
U.S.$1.682 average of the closing bid price of Biomira common shares as
quoted on the Nasdaq National Market for the five trading days up to and
including September 18, 2003.
The issue will include up to 2,070,000 warrants. Each purchaser
participating in the offering will receive 0.23 warrants for every common
share purchased in the offering. Each warrant will entitle the holder
thereof to purchase one common share at an exercise price of U.S. $2.30.
The warrants will have a two year term, expiring September 18, 2005, and a
"no exercise period" of six months.
"Our financial goal is to have sufficient funds to aggressively move our
two lead product candidates to the next level," said Edward Taylor, Vice
President Finance and Chief Financial Officer. "With the completion of
this additional financing, we feel we are well on the way to accomplishing
that goal."
Biomira is a biotechnology company specializing in the development of
innovative therapeutic approaches to cancer management. Biomira's
commitment to the treatment of cancer currently focuses on the development
of synthetic vaccines and novel strategies for cancer immunotherapy. We
are The Cancer Vaccine People™.
This release may contain forward-looking statements. Various factors could
cause actual results to differ materially from those projected in
forward-looking statements, including those predicting the timing and
results of clinical trials, availability or adequacy of financing, the
sales and marketing of commercial products or the efficacy of products.
Although the Company believes that the forward-looking statements contained
herein are reasonable, it can give no assurance that the Company's
expectations are correct. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement.
ودي استثمر فيه 500 الف ريال ومتردد لكن سعره 1.85 دولار
اتمنى القى رد منكم اخي سيف العجمي
وبالتوفيق للجميع وتحياتي